自然殺手細胞療法市場報告：治療方法、應用、最終用戶和地區分類（2026-2034 年）

2025年，全球自然殺手細胞療法市場規模達35億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到92億美元，2026年至2034年的複合年成長率為10.89%。癌症風險上升和人口老化是推動市場成長的主要因素。

自然殺手細胞療法市場的發展趨勢：

聯合治療的日益普及

為了提高治療效果，將NK細胞療法與其他治療方法結合的方法正受到廣泛關注。例如，Innate Pharma公司的抗CD22免疫毒素「Lumoxiti」與NK細胞聯合使用，用於靶向並摧毀毛細胞白血病中表達CD22的癌細胞。此外，這種方法充分利用了兩種療法的優勢。另外，2024年5月，致力於開發用於自體免疫疾病、癌症和感染疾病的創新細胞療法平台的生物製藥公司Coeptis Therapeutics Holdings, Inc.宣布推出靶向多種抗原的SNAP-CAR NK細胞。

監管核准增加

推動市場成長的關鍵因素之一是政府機構日益重視提高NK細胞生產的可靠性和效率。此外，政府機構鼓勵將實驗室研究成果轉化為實際的臨床治療方案，這將在可預見的未來繼續推動市場發展。例如，2024年4月，下一代NK細胞療法領域的領先創新者Ingenium Therapeutics獲得了美國食品藥物管理局（FDA）授予的治療急性骨髓性白血病（AML）的孤兒藥資格認定。

即時監控的需求日益成長

在NK細胞療法研發中，即時監測和數據分析的廣泛應用正在提高治療的精準度和患者療效。此外，像Bio-Techne公司的Ella系統這樣的平台能夠精確監測NK細胞增殖過程中細胞激素的產生，確保細胞的最佳功能。即時分析還允許研究人員動態調整培養條件，有助於提高所生產NK細胞的品質和療效。這正在對市場產生正面影響。

目錄

第1章：序言

第2章：調查方法

• 調查目的
• 相關利益者
• 數據來源
  • 主要訊息
  • 次要訊息
• 市場估值
  • 自下而上的方法
  • 自上而下的方法
• 預測方法

第3章執行摘要

第4章：引言

第5章：全球自然殺手細胞療法市場

• 市場概覽
• 市場表現
• 新冠疫情的影響
• 市場預測

第6章 市場區隔：依治療領域分類

• NK細胞療法
• NK細胞標靶抗體

第7章 市場區隔：依應用領域分類

• 癌症
• 消化系統疾病
• 免疫增生性疾病
• 其他

第8章 市場區隔：依最終用戶分類

• 醫院
• 研究機構
• 其他

第9章 市場區隔：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳洲
  • 印尼
  • 其他
• 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他
• 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

• 市場結構
• 大公司
• 主要公司簡介
  • Affimed GmbH
  • Bristol-Myers Squibb Company
  • Fate Therapeutics
  • Fortress Biotech Inc.
  • Glycostem Therapeutics
  • Innate Pharma SA
  • Kuur Therapeutics Inc.（Athenex Inc.）
  • Nkarta Inc.
  • Takeda Pharmaceutical Company Limited
  • Ziopharm Oncology Inc.

The global natural killer cells therapeutics market size reached USD 3.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 9.2 Billion by 2034, exhibiting a growth rate (CAGR) of 10.89% during 2026-2034. The rising risks of developing cancer, along with the expanding geriatric population, are propelling the market.

Natural Killer Cells Therapeutics Market Trends:

Increasing Popularity of Combination Therapies

Combining NK cell therapies with other treatment modalities to enhance therapeutic efficacy is gaining extensive traction. For example, Innate Pharma's Lumoxiti, an anti-CD22 immunotoxin, is adopted in conjunction with NK cells to destroy and target CD22-expressing cancer cells in hairy cell leukemia. Moreover, this approach leverages the strengths of both therapies. Besides this, in May 2024, Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for autoimmune, cancer, and infectious diseases, introduced SNAP-CAR NK cells to target multiple antigens.

Growing Regulatory Approval

The rising focus among government agencies on enhancing the reliability and efficiency of NK cell production is acting as a significant growth-inducing factor. Furthermore, they are encouraging the translation of laboratory research into viable clinical therapies, which will continue to fuel the market over the foreseeable future. For example, in April 2024, Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

Rising Demand for Real-Time Monitoring

The widespread integration of real-time monitoring and data analytics into NK cell therapy development is enhancing treatment precision and patient outcomes. Moreover, platforms like Bio-Techne's Ella system enable precise monitoring of cytokine production during NK cell expansion, thereby ensuring optimal cell functionality. Real-time analytics also allow researchers to adjust culture conditions dynamically, which aids in improving the quality and effectiveness of the NK cells produced. This is positively influencing the market.

Global Natural Killer Cells Therapeutics Industry Segmentation:

The publisher provides an analysis of the key trends in each segment of the market, along with the natural killer cells therapeutics market forecast at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on therapeutics, application, and end user.

Breakup by Therapeutics:

• NK Cell Therapies
• NK Cell Directed Antibodies

Currently, NK cell directed antibodies hold the majority of the total market share

NK cell directed antibodies target natural killer cells to enhance their ability to recognize and destroy cancer cells. For example, Affimed's AFM13, a bispecific NK cell engager, targets CD30 on cancer cells and CD16A on NK cells.

Breakup by Application:

• Cancer
• Gastrointestinal Diseases
• Immunoproliferative Disorders
• Others

Cancer currently exhibits a clear dominance in the market

The inflating need for effective cancer treatments drives the segment's growth. Recent product launches have underscored the potential of NK cell-based therapies in oncology. For instance, Fate Therapeutics' FT596 is an off-the-shelf, iPSC-derived NK cell therapy designed to target multiple cancer types, including B-cell malignancies.

Breakup by End User:

• Hospitals
• Research Centers and Institutes
• Others

Currently, research centers and institutes hold the majority of the total market share

Research centers and institutes offer high-quality reagents and technologies that streamline NK cell research, which is increasing the natural killer cells therapeutics market share. For example, Bio-Techne's Cloudz Human NK Cell Expansion Kit allows researchers to expand NK cells ex vivo efficiently.

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

Advancements in biotechnology and a strong focus on innovative cancer treatments are primarily catalyzing the market in North America. According to the publisher, the United States cancer immunotherapy market size is projected to exhibit a growth rate (CAGR) of 10.90% during 2024-2032. Besides this, collaborations between biotech firms are strengthening the regional market.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• Affimed GmbH
• Bristol-Myers Squibb Company
• Fate Therapeutics
• Fortress Biotech Inc.
• Glycostem Therapeutics
• Innate Pharma S.A.
• Kuur Therapeutics Inc. (Athenex Inc.)
• Nkarta Inc.
• Takeda Pharmaceutical Company Limited
• Ziopharm Oncology Inc.

Key Questions Answered in This Report

• 1.What was the size of the global natural killer cells therapeutics market in 2025?
• 2.What is the expected growth rate of the global natural killer cells therapeutics market during 2026-2034?
• 3.What are the key factors driving the global natural killer cells therapeutics market?
• 4.What has been the impact of COVID-19 on the global natural killer cells therapeutics market?
• 5.What is the breakup of the global natural killer cells therapeutics market based on the therapeutics?
• 6.What is the breakup of the global natural killer cells therapeutics market based on the application?
• 7.What is the breakup of the global natural killer cells therapeutics market based on the end user?
• 8.What are the key regions in the global natural killer cells therapeutics market?
• 9.Who are the key players/companies in the global natural killer cells therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Natural Killer Cells Therapeutics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Therapeutics

• 6.1 NK Cell Therapies
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 NK Cell Directed Antibodies
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Application

• 7.1 Cancer
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Gastrointestinal Diseases
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Immunoproliferative Disorders
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Research Centers and Institutes
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Affimed GmbH
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Bristol-Myers Squibb Company
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Fate Therapeutics
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
  • 14.3.4 Fortress Biotech Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 Glycostem Therapeutics
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Innate Pharma S.A.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 Kuur Therapeutics Inc. (Athenex Inc.)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Nkarta Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
  • 14.3.9 Takeda Pharmaceutical Company Limited
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Ziopharm Oncology Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials

List of Figures

• Figure 1: Global: Natural Killer Cells Therapeutics Market: Major Drivers and Challenges
• Figure 2: Global: Natural Killer Cells Therapeutics Market: Sales Value (in Billion USD), 2020-2025
• Figure 3: Global: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Billion USD), 2026-2034
• Figure 4: Global: Natural Killer Cells Therapeutics Market: Breakup by Therapeutics (in %), 2025
• Figure 5: Global: Natural Killer Cells Therapeutics Market: Breakup by Application (in %), 2025
• Figure 6: Global: Natural Killer Cells Therapeutics Market: Breakup by End User (in %), 2025
• Figure 7: Global: Natural Killer Cells Therapeutics Market: Breakup by Region (in %), 2025
• Figure 8: Global: Natural Killer Cells Therapeutics (NK Cell Therapies) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 9: Global: Natural Killer Cells Therapeutics (NK Cell Therapies) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 10: Global: Natural Killer Cells Therapeutics (NK Cell Directed Antibodies) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 11: Global: Natural Killer Cells Therapeutics (NK Cell Directed Antibodies) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 12: Global: Natural Killer Cells Therapeutics (Cancer) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 13: Global: Natural Killer Cells Therapeutics (Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 14: Global: Natural Killer Cells Therapeutics (Gastrointestinal Diseases) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 15: Global: Natural Killer Cells Therapeutics (Gastrointestinal Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 16: Global: Natural Killer Cells Therapeutics (Immunoproliferative Disorders) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 17: Global: Natural Killer Cells Therapeutics (Immunoproliferative Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 18: Global: Natural Killer Cells Therapeutics (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 19: Global: Natural Killer Cells Therapeutics (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 20: Global: Natural Killer Cells Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 21: Global: Natural Killer Cells Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 22: Global: Natural Killer Cells Therapeutics (Research Centers and Institutes ) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 23: Global: Natural Killer Cells Therapeutics (Research Centers and Institutes ) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 24: Global: Natural Killer Cells Therapeutics (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 25: Global: Natural Killer Cells Therapeutics (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 26: North America: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 27: North America: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 28: United States: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 29: United States: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 30: Canada: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 31: Canada: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 32: Asia-Pacific: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 33: Asia-Pacific: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 34: China: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 35: China: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 36: Japan: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 37: Japan: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 38: India: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 39: India: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 40: South Korea: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 41: South Korea: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 42: Australia: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 43: Australia: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 44: Indonesia: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 45: Indonesia: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 46: Others: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 47: Others: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 48: Europe: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 49: Europe: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 50: Germany: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 51: Germany: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 52: France: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 53: France: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 54: United Kingdom: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 55: United Kingdom: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 56: Italy: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 57: Italy: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 58: Spain: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 59: Spain: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 60: Russia: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 61: Russia: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 62: Others: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 63: Others: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 64: Latin America: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 65: Latin America: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 66: Brazil: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 67: Brazil: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 68: Mexico: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 69: Mexico: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 70: Others: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 71: Others: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 72: Middle East and Africa: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
• Figure 73: Middle East and Africa: Natural Killer Cells Therapeutics Market: Breakup by Country (in %), 2025
• Figure 74: Middle East and Africa: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 75: Global: Natural Killer Cells Therapeutics Industry: SWOT Analysis
• Figure 76: Global: Natural Killer Cells Therapeutics Industry: Value Chain Analysis
• Figure 77: Global: Natural Killer Cells Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Natural Killer Cells Therapeutics Market: Key Industry Highlights, 2025 and 2034
• Table 2: Global: Natural Killer Cells Therapeutics Market Forecast: Breakup by Therapeutics (in Million USD), 2026-2034
• Table 3: Global: Natural Killer Cells Therapeutics Market Forecast: Breakup by Application (in Million USD), 2026-2034
• Table 4: Global: Natural Killer Cells Therapeutics Market Forecast: Breakup by End User (in Million USD), 2026-2034
• Table 5: Global: Natural Killer Cells Therapeutics Market Forecast: Breakup by Region (in Million USD), 2026-2034
• Table 6: Global: Natural Killer Cells Therapeutics Market: Competitive Structure
• Table 7: Global: Natural Killer Cells Therapeutics Market: Key Players